Samyang Holdings Corp.
- Biotech or pharma, therapeutic R&D
We are pioneering a new generation of non-viral delivery systems, led by our proprietary SENS™ (Selectivity Enabling NanoShell) platform. Built from novel biodegradable polymers and ionizable lipids, SENS™ is engineered for tissue-selective delivery of nucleic acid therapeutics, including mRNA. Its tunable formulation enables targeted delivery to organs like the spleen, lung, muscle, CNS and liver, while offering a superior safety profile that supports repeat dosing, unlocking new potential in RNA-based medicine.
Address
CambridgeMassachusetts
United States
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}